Goldman Sachs
FULC icon

Goldman Sachs’s Fulcrum Therapeutics FULC Stock Holding History

Goldman Sachs’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.01M Buy
1,094,425
+522,516
+91% +$3.18M ﹤0.01% 4083
2026
Q1 		$4.39M Buy
571,909
+248,030
+77% +$2.3M ﹤0.01% 3831
2025
Q4 		$3.66M Sell
323,879
-262,472
-45% -$2.67M ﹤0.01% 4039
2025
Q3 		$5.39M Sell
586,351
-557,185
-49% -$4.03M ﹤0.01% 3564
2025
Q2 		$7.87M Buy
1,143,536
+740,936
+184% +$3.96M ﹤0.01% 2979
2025
Q1 		$1.16M Sell
402,600
-139,658
-26% -$513K ﹤0.01% 4568
2024
Q4 		$2.55M Sell
542,258
-385,703
-42% -$1.42M ﹤0.01% 4075
2024
Q3 		$3.31M Buy
927,961
+367,469
+66% +$2.73M ﹤0.01% 3714
2024
Q2 		$3.48M Sell
560,492
-249,778
-31% -$1.89M ﹤0.01% 3489
2024
Q1 		$7.65M Sell
810,270
-61,233
-7% -$547K ﹤0.01% 2729
2023
Q4 		$5.88M Buy
871,503
+612,276
+236% +$2.72M ﹤0.01% 3020
2023
Q3 		$1.15M Sell
259,227
-128,505
-33% -$562K ﹤0.01% 4175
2023
Q2 		$1.28M Buy
387,732
+89,921
+30% +$264K ﹤0.01% 4181
2023
Q1 		$849K Sell
297,811
-17,617
-6% -$158K ﹤0.01% 4495
2022
Q4 		$2.3M Sell
315,428
-29,302
-8% -$191K ﹤0.01% 3840
2022
Q3 		$2.79M Buy
344,730
+60,425
+21% +$433K ﹤0.01% 3670
2022
Q2 		$1.39M Buy
284,305
+46,663
+20% +$456K ﹤0.01% 4360
2022
Q1 		$5.62M Buy
237,642
+152,759
+180% +$2.16M ﹤0.01% 3241
2021
Q4 		$1.5M Buy
84,883
+22,381
+36% +$443K ﹤0.01% 4496
2021
Q3 		$1.76M Buy
62,502
+35,036
+128% +$664K ﹤0.01% 4306
2021
Q2 		$288K Buy
27,466
+13,099
+91% +$132K ﹤0.01% 5543
2021
Q1 		$169K Sell
14,367
-490
-3% -$6.06K ﹤0.01% 5699
2020
Q4 		$174K Buy
+14,857
New +$168K ﹤0.01% 5133
2019
Q4 		– Sell
-27,871
Closed -$185K – 5284
2019
Q3 		$185K Buy
+27,871
New +$308K ﹤0.01% 4842

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's FULC Position: Q2 2026 in Review

Goldman Sachs increased its Fulcrum Therapeutics (FULC) stake by 91% in Q2 2026, buying an estimated $3.18M and bringing the position to 1,094,425 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4083.

Goldman Sachs first reported a position in FULC in Q3 2019 and has held it in 24 quarters since. The position peaked at $7.87M in Q2 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Goldman Sachs held 1,094,425 shares of Fulcrum Therapeutics worth $4.01M as of Q2 2026.
  • Goldman Sachs bought 522,516 Fulcrum Therapeutics shares in Q2 2026, an estimated $3.18M.
  • Fulcrum Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4083 holding.
  • Goldman Sachs first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 24 quarters since.
  • Goldman Sachs's Fulcrum Therapeutics position peaked at $7.87M in Q2 2025.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.